ANSELL (UNSP.ADRS)/4 (PD1) - Net Assets
Based on the latest financial reports, ANSELL (UNSP.ADRS)/4 (PD1) has net assets worth €1.98 Billion EUR (≈ $2.32 Billion USD) as of June 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€3.32 Billion ≈ $3.88 Billion USD) and total liabilities (€1.34 Billion ≈ $1.57 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check ANSELL (UNSP.ADRS)/4 strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €1.98 Billion |
| % of Total Assets | 59.68% |
| Annual Growth Rate | 8.4% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 6.82 |
ANSELL (UNSP.ADRS)/4 - Net Assets Trend (2022–2025)
This chart illustrates how ANSELL (UNSP.ADRS)/4's net assets have evolved over time, based on quarterly financial data. Explore PD1 long-term investment intensity to see how much of total assets are deployed in long-term investments.
Annual Net Assets for ANSELL (UNSP.ADRS)/4 (2022–2025)
The table below shows the annual net assets of ANSELL (UNSP.ADRS)/4 from 2022 to 2025. For live valuation and market cap data, see PD1 market cap overview.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | €1.98 Billion ≈ $2.32 Billion |
+3.80% |
| 2024-06-30 | €1.91 Billion ≈ $2.23 Billion |
+18.25% |
| 2023-06-30 | €1.62 Billion ≈ $1.89 Billion |
+3.78% |
| 2022-06-30 | €1.56 Billion ≈ $1.82 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to ANSELL (UNSP.ADRS)/4's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 16.5% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €1.10 Billion | 55.88% |
| Other Components | €866.40 Million | 44.12% |
| Total Equity | €1.96 Billion | 100.00% |
ANSELL (UNSP.ADRS)/4 Competitors by Market Cap
The table below lists competitors of ANSELL (UNSP.ADRS)/4 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Unibel S.A
PA:UNBL
|
$2.51 Billion |
|
Rogers Corporation
NYSE:ROG
|
$2.51 Billion |
|
TAG IMMOBILIEN ADR 1/2
F:TEG0
|
$2.51 Billion |
|
Tibet Summit Resources Co Ltd
SHG:600338
|
$2.52 Billion |
|
LG Household & Healthcare
KO:051900
|
$2.51 Billion |
|
American Superconductor Corporation
NASDAQ:AMSC
|
$2.51 Billion |
|
Netweb Technologies India Limited
NSE:NETWEB
|
$2.51 Billion |
|
Customers Bancorp, Inc.
NYSE:CUBI
|
$2.51 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in ANSELL (UNSP.ADRS)/4's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,894,900,000 to 1,963,600,000, a change of 68,700,000 (3.6%).
- Net income of 101,600,000 contributed positively to equity growth.
- Dividend payments of 63,700,000 reduced retained earnings.
- Share repurchases of 4,400,000 reduced equity.
- Other factors increased equity by 35,200,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €101.60 Million | +5.17% |
| Dividends Paid | €63.70 Million | -3.24% |
| Share Repurchases | €4.40 Million | -0.22% |
| Other Changes | €35.20 Million | +1.79% |
| Total Change | €- | 3.63% |
Book Value vs Market Value Analysis
This analysis compares ANSELL (UNSP.ADRS)/4's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.40x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 4.85x to 4.40x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-06-30 | €12.26 | €59.50 | x |
| 2023-06-30 | €12.70 | €59.50 | x |
| 2024-06-30 | €13.04 | €59.50 | x |
| 2025-06-30 | €13.52 | €59.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently ANSELL (UNSP.ADRS)/4 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 5.17%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 5.07%
- • Asset Turnover: 0.60x
- • Equity Multiplier: 1.69x
- Recent ROE (5.17%) is below the historical average (7.19%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | 10.29% | 8.13% | 0.78x | 1.62x | €4.41 Million |
| 2023 | 9.26% | 8.96% | 0.65x | 1.58x | €-11.79 Million |
| 2024 | 4.04% | 4.72% | 0.50x | 1.71x | €-112.99 Million |
| 2025 | 5.17% | 5.07% | 0.60x | 1.69x | €-94.76 Million |
Industry Comparison
This section compares ANSELL (UNSP.ADRS)/4's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $6,199,585,877
- Average return on equity (ROE) among peers: -8.85%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| ANSELL (UNSP.ADRS)/4 (PD1) | €1.98 Billion | 10.29% | 0.68x | $2.51 Billion |
| SCHOTT Pharma AG & Co. KGaA (1SXP) | $419.42 Million | 24.02% | 0.76x | $2.39 Billion |
| RENAU.UNSP.ARD 1/5 EO-20 (56S0) | $2.67 Billion | 11.61% | 1.89x | $15.47 Billion |
| MEDIMI AB AK (79T) | $13.75 Million | -103.63% | 0.50x | $365.27K |
| TEVANO SYSTEMS HLDGS INC. (7RBA) | $-938.43K | 0.00% | 0.00x | $210.67K |
| STEVANATO GROUP SPA O.N. (87N) | $841.66 Million | 15.96% | 0.69x | $894.98 Million |
| Carl Zeiss Meditec AG (AFX) | $2.06 Billion | 8.69% | 0.65x | $2.23 Billion |
| CARL ZEISS MEDITEC ADR 1 (AFXA) | $2.17 Billion | 13.36% | 0.40x | $2.14 Billion |
| Bio-gate AG (BIG1) | $1.79 Million | -90.74% | 1.21x | $7.08 Million |
| COLOPLAST SP.ADR 1/10 DK1 (CBH) | $17.94 Billion | 28.16% | 1.68x | $12.73 Billion |
| ESSILORLUXOTTICA 1/2/O.N. (ESLC) | $35.88 Billion | 4.04% | 0.66x | $78.07 Billion |
About ANSELL (UNSP.ADRS)/4
Ansell Limited designs, sources, develops, manufactures, distributes, and sells hand and body protection solutions in the Asia Pacific, Europe, the Middle East, Africa, Latin America, the Caribbean, and North America. It operates through two segments: Healthcare and Industrial. The Healthcare segment manufactures and markets solutions, including surgical gloves, single-use and examination gloves,… Read more